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Background: Struma ovarii (SO) is a rare form of ovarian mature teratoma in which thyroid tissue is the
predominant element. Because of its rarity, the differential diagnosis between benign and malignant SO has not
been clearly defined. It is believed that malignant transformation of SO has similar molecular features with and its
prognosis corresponds to that of malignant tumors originating in the thyroid.
Case presentation: We report 35-year-old woman with bilateral ovarian cysts incidentally detected by ultrasound
during the first trimester of pregnancy. Four months after delivery of a healthy child without complication she was
admitted to the hospital for acute abdominal pain. Laparoscopic left adnexectomy was performed initially in a
regional hospital; right cystectomy was done later in a specialized clinic. Intraoperative frozen section and a final
pathology revealed that the cyst from the left ovary was composed of mature teratomatous elements, normal
thyroid tissue (>50%) and a non-encapsulated focus of follicular variant of papillary thyroid carcinoma (PTC).
Normal and cancerous thyroid tissues were tested for BRAF and RAS mutations by direct sequencing, and for
RET/PTC rearrangements by RT-PCR/Southern blotting. A KRAS codon 12 mutation, the GGT!GTT transversion,
corresponding to the Gly! Val amino acid change was identified in the absence of other genetic alterations
commonly found in PTC.
Conclusion: To the best of our knowledge, this is the first time this mutation is described in a papillary thyroid
carcinoma arising in struma in the ovarii. This finding provides further evidence that even rare mutations specific for
PTC may occur in such tumors. Molecular testing may be a useful adjunct to common differential diagnostic
methods of thyroid malignancy in SO.
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Struma ovarii (SO) is a rare form of ovarian teratoma
where thyroid tissue forms a grossly detectible mass or
is the major cellular component (>50%). Teratomas
comprise approximately 95% of germ cell tumors of
which SO accounts for only 3% [1,2]. The differential
diagnosis between benign and malignant SO may be dif-
ficult due to the lack of uniform diagnostic criteria [3].
The real incidence of malignancy in SO is unclear be-
cause of its rarity but the existing literature indicates
that 5%–10% of such tumors are malignant with papil-
lary and less frequently, follicular carcinoma being the
most common [1-4]. It is believed that malignant trans-
formation of SO has similar molecular features with and
its prognosis corresponds to that of malignant tumors
originating in the thyroid [5,6]. The molecular pathogen-
esis of papillary thyroid carcinomas (PTC) is largely
associated with genetic alterations in the RET-RAS-
RAF-MAPK pathway usually caused by RET/PTC rear-
rangements (13%–43%) or activating point mutations in
the BRAF (29%–83%) or RAS-family genes (0 %–21 %).
These molecular alterations occur cumulatively in up to
70% of all follicular cell-derived thyroid carcinomas in a
nearly mutually exclusive manner [6-9].
Case presentation
The patient is a 35-year-old woman (gravida 1, para 0,
abortus 0) who during the first trimester of pregnancy
was diagnosed for bilateral ovarian cysts detected inci-
dentally by ultrasound. She had no significant medical or
gynecological history before and was clinically and bio-
chemically euthyroid with normal serum TSH level. Four
months after delivery of a healthy child without a compli-
cation she was admitted to the hospital for acute abdom-
inal pain. Laboratory data showed normal biochemical
parameters and complete blood count. The plasma level
of CA-125 was slightly elevated to 42.72 U/ml (35 U/mL,
the upper normal limit). An ultrasound scan showed an
enlarged left ovary and cystic masses in both ovaries. The
patient was operated in December 2008 in a regional
hospital where laparoscopic left adnexectomy wasFigure 1 a. Teratoma tissue with mature epidermis (E), sebaceous gla
tissue (PTC) (H&E 40x). b. Fragment of PTC in SO featuring solid-trabeculinitially performed. Intraoperative frozen section path-
ology revealed that the cyst was composed of mature ter-
atomatous elements including epidermis, sebaceous
glands, adipose, normal thyroid tissue (>50%) and a
10 mm non-encapsulated cancerous focus (which was
confirmed later to be the FV-PTC on final pathology,
Figure 1a and 1b) [10-12]. Because of the finding of can-
cer the surgeon made a decision not to proceed with the
right oophorectomy and to transfer the patient to specia-
lized oncology clinic.
The tumor from the left ovary showed immunoreactiv-
ity to thyroglobulin and thyroid transcription factor-1
(all antibodies from Dako, Carpinteria, CA, USA, data
not shown). For molecular investigation 5 μm sections
were taken, dewaxed, and lightly stained with
hematoxylin and eosin. Normal thyroid tissue and PTC
area were manually dissected from 3 serial sections.
DNA was extracted using Gentra Puregene Tissue kit
(Quiagen, Minneapolis, MN, USA). Total RNA was
extracted using Recover All Total Nucleic Acid Isolation
Kit (Ambion, Applied Biosystems, Foster City, CA,
USA). DNA from the tumor and adjacent benign thyroid
tissue was tested by PCR/direct sequencing of genomic
DNA for genetic abnormalities that have been described
in thyroid cancer originating in the neck, including a
portion of BRAF exon 15 and codons 12, 13, 31, 60 and
61 of K-, H- and N-RAS. RET/PTC1 and RET/PTC3
rearrangements were detected using reverse transcrip-
tion-polymerase chain reaction (RT-PCR) followed by
Southern blotting. This tumor was found to harbor a
KRAS codon 12 mutation, the GGT!GTT transver-
sion, corresponding to the Gly!Val amino acid change
(Figure 2). No mutations were found in adjacent be-
nign thyroid tissue. All experimental techniques and
primer sequences used were essentially as previously
described [13].
Case was presented to the multidisciplinary committee
at the Institute of Oncology and Radiology of Serbia
who decided the patient should undergo reoperation for
the right ovarian cyst measuring 80 mm, which was also
present at the time of the first surgery. The patient wasnds (S), adipose tissue (A) normal (N) and malignant thyroid
ar and follicular growth patterns (H&E 100x).
Figure 2 KRAS codon 12 mutation, GGT!GTT, corresponding to the Gly!Val amino acid change.
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median laparatomy a macroscopically enlarged right
ovary was verified to contain two cysts. The larger cyst
measured 50x45x25 mm and contained soft whitish
material. Histology report confirmed benign ovarian
cyst with no evidence of other abnormality. An intra-
operative frozen section and final pathology of the sec-
ond smaller cyst 30x25x20 mm in size revealed mature
cystic teratoma with benign thyroid tissue. Other tissue
components included hair, adipose tissue, cartilage,
bone and skin. Both cysts were removed and the right
ovary was preserved. Multiple biopsies of the greater
omentum, iliac lymph nodes, peritoneum above the
urinary bladder and cul de sac showed no signs of ma-
lignant spread. Postoperative thyroid function blood
test showed normal TSH, calcitonin, thyroglobulin and
thyroglobulin antibody levels. Neck ultrasonography
revealed a solitary thyroid nodule (6x4 mm) located
caudally in the left lobe without signs of enlarged cen-
tral and jugulo-carotid lymph nodes. No evidence of
distant metastases was found on abdominal ultrasonog-
raphy and chest X-ray. The patient is currently well,
without evidence of disease progression one year after
the second surgery. She is closely followed up under-
going clinical, radiologic and laboratory examinations
every 6 months. At present, the patient is planned for
fine needle aspiration biopsy; total thyroidectomy is
considered as a further treatment modality [14].
Conclusion
Thyroid-type carcinoma in SO is rare. Only 6% of cases
of malignant transformation in struma ovarii are bilat-
eral and the tumors arise more commonly in the left
ovary than in the right [1,2,4]. In the described case thetumor was unilateral on the left side. Due to the rarity
of the tumor, the real incidence of malignancy, patho-
biology and molecular profile of thyroid cancer arising
in the ovary remain poorly studied.
Thus far only a few studies have analyzed genetic
alterations in thyroid-type carcinoma in SO. Previous
case series describe the presence of point mutations in
BRAF, NRAS, HRAS, and RET/PTC rearrangements but
none in the KRAS gene [6,15-17]. The present report
therefore describes for the first time a KRAS codon 12
mutation in a case of PTC with a follicular growth
pattern arising in SO in combination with bilateral
teratoma [10-12].
The prevalence of RAS gene family mutations in thy-
roid-originating PTC ranges from 0 to 21% in different
series (about 11% on average) [18,19]. The highest fre-
quency of RAS mutations has been found in the follicu-
lar variant of PTC (43%) while in the tumors with other
morphology they are not so common [20]. Alterations
most frequently involve codon 61 of HRAS and NRAS
and less frequently codons 12 and 13; mutations of
KRAS are very rare in general [21-23]. In line with these
observations, our previous study in Serbian patients
detected RAS mutations in 6/218 (2.8%) classical papil-
lary tumors and 5/44 (11.4%) follicular variant PTCs.
Most detected mutations were in codon 61 of NRAS
(8/11, 72.7%) and 3/11 (17.3%) were in codon 12 of
KRAS [13].
Thyroid tumors with mutant RAS are frequently
encapsulated and display a lower rate of nodal disease
which are favorable prognostic factors. On the other
hand, RAS mutations are also found in approximately
one-half of poorly differentiated and anaplastic thyroid
carcinomas and are associated with poor patient survival,
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and late stage of thyroid cancer [19,20,24]. Several stud-
ies have demonstrated that tumors carrying any of mu-
tant forms of KRAS are associated with a poor prognosis
in a number of human malignancies [24,25]. Analyzing
these reports, we found that a glycine to valine mutation
at codon 12 of the KRAS gene, the same mutation that
we describe in this report, associates with poor survival
in colon cancer [25] suggesting that this mutation may
represent a marker of tumor aggressiveness, perhaps in
thyroid cancer as well.
On the other hand, BRAF mutations or RET/PTC rear-
rangements are commonly seen in thyroid cancer arising
in struma ovarii. In one of the largest and most signifi-
cant studies to date, Schmidt et al., showed that every
PTC in SO with the classical growth pattern had the
BRAFV600E mutation, and the two mutant BRAF-harbor-
ing tumors with follicular architecture had BRAFK601E
and BRAFTV599–600M mutation. No follicular carcinomas
were identified in this study. Genetic alteration in benign
SO has been seen in only one case in the literature. Elisei
et al. recently reported the presence of RET/PTC3 re-
arrangement in histologically benign tissue. In carcin-
omas of the thyroid, numerous studies have suggested,
although equivocally, that BRAF mutation associates with
the older age, advanced disease, classical papillary hist-
ology and poorer prognosis as indicated by disease-free
and overall survival [8,9]. The presence of RET/PTC re-
arrangement correlates with some clinicopathological
features of PTC such as younger age of patients, tumor
morphology and a higher probability of lymph node in-
volvement [26]. No studies have as yet correlated RAS
and BRAF mutational status or the presence of RET/PTC
rearrangements with clinical behavior in thyroid-type
carcinoma arising in SO. However, it is generally
assumed that clinical behavior and prognosis of these
tumors are similar to those of tumors arising in the
thyroid [6,15-17].
In our study, we describe an unusual case of KRAS
mutation-harboring FV-PTC in a patient with bilateral
ovarian teratoma. This mutation has not been previously
reported in any SO, although it is sometimes detected in
PTC of the thyroid and in a variety of other tumor types.
Analysis of more cases and a longer period of follow-up
will be necessary to determine whether this mutation
has prognostic or therapeutic value.Consent
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